About von Willebrand Disease: What is VWD?The Humate-P® Difference: High Quality and QuantityView a Video Demonstration on How to Self-infuseMix2Vial™The CSL Behring CommitmentResources and ToolsRequest More InformationPatient MaterialsAllAboutBleeding.comGlossary of TermsNews and EventsImportant Safety InformationPrescribing InformationRequest More InformationFor Healthcare Professionals

Request More Information

If your question is about a medical condition, then you should consult with a healthcare professional or, in the case of an emergency, call 911 immediately.
Please Contact Us for additional information.

All fields marked with an asterisk (*) are required.




  • Educational Materials

    I would like the following educational materials sent to me. (If you would like to request additional quantities, please contact Consumer Affairs at 1-888-508-6978.)





  •    

Important Safety Information


Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

© CSL Behring 2010. The product information presented on this site is intended for US residents only.